Targeting eosinophils in chronic respiratory diseases using nanotechnology-based drug delivery

Parvarish Sharma, Daljeet Singh Dhanjal, Chirag Chopra, Murtaza M. Tambuwala, Sukhwinder Singh Sohal, Peter J. van der Spek, Hari S. Sharma, Saurabh Satija

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)
45 Downloads (Pure)


Asthma, COPD, COVID-19, EGPA, Lung cancer, and Pneumonia are major chronic respiratory diseases (or CRDs) affecting millions worldwide and account for substantial morbidity and mortality. These CRDs are irreversible diseases that affect different parts of the respiratory system, imposing a considerable burden on different socio-economic classes. All these CRDs have been linked to increased eosinophils in the lungs. Eosinophils are essential immune mediators that contribute to tissue homeostasis and the pathophysiology of various diseases. Interestingly, elevated eosinophil level is associated with cellular processes that regulate airway hyperresponsiveness, airway remodeling, mucus hypersecretion, and inflammation in the lung. Therefore, eosinophil is considered the therapeutic target in eosinophil-mediated lung diseases. Although, conventional medicines like antibiotics, anti-inflammatory drugs, and bronchodilators are available to prevent CRDs. But the development of resistance to these therapeutic agents after long-term usage remains a challenge. However, progressive development in nanotechnology has unveiled the targeted nanocarrier approach that can significantly improve the pharmacokinetics of a therapeutic drug. The potential of the nanocarrier system can be specifically targeted on eosinophils and their associated components to obtain promising results in the pharmacotherapy of CRDs. This review intends to provide knowledge about eosinophils and their role in CRDs. Moreover, it also discusses nanocarrier drug delivery systems for the targeted treatment of CRDs.
Original languageEnglish
Article number110050
JournalChemico-Biological Interactions
Early online date30 Jul 2022
Publication statusPublished (in print/issue) - 25 Sept 2022

Bibliographical note

Funding Information:
This work is supported by Lovely Professional University, India from undergraduate students capstone projects grants (Sharma P and Satija S). This work is completed with the help of Sohal S.S of University of Tasmania, Australia who is supported by the grants from Clifford Craig Foundation Launceston General Hospital , Rebecca L. Cooper Medical Research Foundation , Lung Foundation Australia , and LAM Australia Research Alliance .

Publisher Copyright:
© 2022


  • Chronic respiratory diseases (CRDs)
  • Eosinophils
  • Inflammation
  • Nano-carriers
  • Target drug delivery


Dive into the research topics of 'Targeting eosinophils in chronic respiratory diseases using nanotechnology-based drug delivery'. Together they form a unique fingerprint.

Cite this